Literature DB >> 3936039

Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.

M A Liu, D M Kranz, J T Kurnick, L A Boyle, R Levy, H N Eisen.   

Abstract

Antibodies to the clonally unique variable-region determinants (idiotype) of the antigen-specific alpha beta heterodimeric receptor of a clone of cytotoxic T cells (CTLs) were shown previously to render diverse cells, regardless of their own surface antigens, susceptible to lysis by that clone of CTLs. To extend these findings, we have sought to develop a general means for targeting cells for destruction by any CTL, without regard to its alpha beta idiotype and specificity for antigen. We explored the use of heteroantibody duplexes formed by joining covalently an antibody to the T3 complex (anti-T3), which is associated with the alpha beta receptors on all human mature T cells, and a second antibody, specific for an antigen on the intended target cell. The second antibody selected in this study was specific for the idiotype (Id) of the surface immunoglobulin of a human B-lymphoma (anti-Ig Id). In the presence of the anti-T3/anti-Ig Id heteroantibody duplex the B-lymphoma cells were lysed by a clone of human T8+ CTLs (of unrelated specificity) but not by a noncytotoxic clone of human T4+ helper T cells, and lysis by the CTLs was specifically blocked by the uncoupled anti-T3 or the uncoupled anti-Ig Id antibodies. The extent of the heteroantibody-dependent cytolysis depended both on the heteroantibody concentration and on whether the intended target cells or the CTL effectors were initially preincubated with the heteroantibody. Under optimal conditions, heteroantibody-dependent lysis of the surrogate target (B-lymphoma) cells by the CTLs compared favorably with lysis of their natural target cells by the same CTLs. Overall, our findings suggest that heteroantibody duplexes containing anti-T3 antibody may be capable of targeting selected cells, such as tumor cells, for destruction in vivo by the body's CTLs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936039      PMCID: PMC391493          DOI: 10.1073/pnas.82.24.8648

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Long term growth in vitro of human T cell blasts with maintenance of specificity and function.

Authors:  J T Kurnick; K O Grönvik; A K Kimura; J B Lindblom; V T Skoog; O Sjöberg; H Wigzell
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

Review 2.  Inhibition of human T lymphocyte function with monoclonal antibodies.

Authors:  D W Dongworth; A J McMichael
Journal:  Br Med Bull       Date:  1984-07       Impact factor: 4.291

Review 3.  Internal disintegration model of cytotoxic lymphocyte-induced target damage.

Authors:  J H Russell
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

4.  Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex.

Authors:  E L Reinherz; S Meuer; K A Fitzgerald; R E Hussey; H Levine; S F Schlossman
Journal:  Cell       Date:  1982-10       Impact factor: 41.582

5.  Preparation of protein conjugates via intermolecular disulfide bond formation.

Authors:  T P King; Y Li; L Kochoumian
Journal:  Biochemistry       Date:  1978-04-18       Impact factor: 3.162

6.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody.

Authors:  P Perez; R W Hoffman; S Shaw; J A Bluestone; D M Segal
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

7.  Immunoglobulin secretion by mouse X human hybridomas: an approach for the production of anti-idiotype reagents useful in monitoring patients with B cell lymphoma.

Authors:  S Brown; J Dilley; R Levy
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

8.  Characterization of in vivo-activated allospecific T lymphocytes propagated from human renal allograft biopsies undergoing rejection.

Authors:  T G Mayer; A A Fuller; T C Fuller; A I Lazarovits; L A Boyle; J T Kurnick
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.

Authors:  A Hatzubai; D G Maloney; R Levy
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  15 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.

Authors:  S A Möller; R A Reisfeld
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Herman N. Eisen: Mentor to many.

Authors:  David M Kranz; Yuri Sykulev
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-23       Impact factor: 11.205

5.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

Authors:  G Jung; C J Honsik; R A Reisfeld; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

7.  Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

Authors:  C F Scott; W A Blättler; J M Lambert; R S Kalish; C Morimoto; S F Schlossman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

8.  Glycosylation of the T-cell antigen-specific receptor and its potential role in lectin-mediated cytotoxicity.

Authors:  S C Hubbard; D M Kranz; G D Longmore; M V Sitkovsky; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells.

Authors:  L S Zalman; D E Martin; G Jung; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Authors:  L K Gilliland; M R Clark; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.